roche · •approved in ppms & rms (us) •positive early feedback from all stakeholders hy...

Roche

HY 2017 results

Basel, 27 July 2017

3

This presentation contains certain forward-looking statements. These forward-looking

statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’,

‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among

other things, strategy, goals, plans or intentions. Various factors may cause actual results to

differ materially in the future from those reflected in forward-looking statements contained in

this presentation, among others:

1 pricing and product initiatives of competitors;

2 legislative and regulatory developments and economic conditions;

3 delay or inability in obtaining regulatory approvals or bringing products to market;

4 fluctuations in currency exchange rates and general financial market conditions;

5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

6 increased government pricing pressures;

7 interruptions in production;

8 loss of or inability to obtain adequate protection for intellectual property rights;

9 litigation;

10 loss of key executives or other employees; and

11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to

mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily

match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website

www.roche.com

All mentioned trademarks are legally protected.

4

Group Severin Schwan Chief Executive Officer

HY 2017 performance

Outlook

5

HY 2017: A strong start into the year

Guidance raised

6

Group sales growth CHF 0.5bn from recent launches* +5%

Core EPS growth Strong underlying business momentum,

divestments partially offsetting PSI +6%

Cash flow Strong operating free cash flow

generation +37%

IFRS net income Strong operating performance partially

offset by impairments +2%

* Tecentriq, Ocrevus, Alecensa

At constant exchange rates (CER); PSI=Past Service Income

HY 2017: Strong sales growth in both divisions

7 CER=Constant Exchange Rates

HY 2017 HY 2016

CHFbn CHFbn CHF CER

Pharmaceuticals Division 20.5 19.5 5 5

Diagnostics Division 5.8 5.6 5 5

Roche Group 26.3 25.0 5 5

Change in %

Q2 2017: Sales growth for the sixth consecutive

year

8

2%

6%

4%

6% 6%

4%

8%

7%

5%

4%

5%

6%

5%

7%

6%

4% 4%

6%

3% 3%

4%

6%

0%

2%

4%

6%

8%

10%

Q1

12

Q2

12

Q3

12

Q4

12

Q1

13

Q2

13

Q3

13

Q4

13

Q1

14

Q2

14

Q3

14

Q4

14

Q1

15

Q2

15

Q3

15

Q4

15

Q1

16

Q2

16

Q3

16

Q4

16

Q1

17

Q2

17

All growth rates at Constant Exchange Rates (CER)

HY 2017: Strong sales growth in US and

International

9

0

2

4

6

8

10

12

Japan International Europe US

Diagnostics

Pharma

CHFbn

+8%

0% +5%

0%

+1% +12%

+2%

0%

+7%

+1%

0%

+7%


HY 2017: Successful launch activities

Differentiation driving growth

10

• ALEX: Superiority in 1L vs Standard of Care

• 1 L recommendation on NCCN guidelines

• CHMP recommendation in bladder (1/2L) & lung (2L),

ongoing market share gains in lung cancer (US)

• Approved in PPMS & RMS (US)

• Positive early feedback from all stakeholders

HY 2017 additional sales

of recent launches

+0.5bn

Ocrevus

+0.2bn

Alecensa

+0.1bn

Tecentriq

+0.2bn

CHF

PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=national comprehensive cancer network;

CHMP=committee for medicinal products for human use

Total:

HY 2017: Major read-outs securing future growth

11

• Perjeta – APHINITY: 19% risk reduction of recurrence/death

after 3 years, further improvement with longer follow up Perjeta

(Early breast cancer)

• Emicizumab - HAVEN1 (Adults) and HAVEN2 (Pediatric):

Details presented at ISTH, filed in US, EU and Japan emicizumab

(Hem. A inhibitors)

SC=subcutaneous; ODAC=oncologic drug advisory committee

• Alecensa - ALEX: Superiority in 1L vs Standard of Care

• Recommended as 1st choice in 1L (ALK+) in NCCN guidelines Alecensa

(ALK+ lung cancer)

• Approved in US after the unanimous recommendation by

ODAC

Rituxan Hycela

(SC)


HY 2017: Strong Core operating profit

9.2 9.9

10.1

HY 2015 HY 2016 HY 2017

CHFbn

% of sales 39.2% 39.4%

38.5%

+3% at CER

HY 2017: Core EPS growth above sales growth

13

7.22 7.74

8.23

HY 2015 HY 2016 HY 2017

CHF


+6% at CER

Roche significantly advancing patient care

Recognition for innovation 2013-present

14

Rank Company #

1 Roche 16

2 Novartis 12

3 BMS 10

4 Merck 9

5 AbbVie 7

5 Pfizer 7

16 Breakthrough Therapy Designations

Year Molecule

2017 Zelboraf (BRAF-mutated ECD)

Rituxan (Pemphigus vulgaris)

2016

Actemra (Giant cell arteritis)

Alecensa (1L ALK+ NSCLC)

Ocrevus (PPMS)

Venclexta (AML)

Venclexta + Rituxan (R/R CLL)

2015

Actemra (Systemic sclerosis)

Tecentriq (NSCLC)

Venclexta (R/R CLL 17p del)

Emicizumab/ACE 910 (Hemophilia A)

2014

Esbriet (IPF)

Lucentis (Diabetic retinopathy)

Tecentriq (Bladder)

2013 Alecensa (2L ALK+ NSCLC)

Gazyva (1L CLL)

Source: http://www.focr.org/breakthrough-therapies as of June 30, 2017; PPMS=Primary Progressive Multiple Sclerosis; CLL=Chronic

Lymphocytic Leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Fibrosis; ECD=Erdheim-Chester disease

http://www.focr.org/breakthrough-therapies



HY 2017 performance

Outlook

15

Launch of new medicines at a record high

2011 2012 2013 2014 2015 2016 2017

Emicizumab

(filed)

16

2017: Another important year for our pipeline

Key read-outs

Q1 Q2 Q3 Q4

IMpower150 (Tecentriq 1L Lung)

APHINITY (Perjeta early BC, Her2+)

SPECTRI & CHROMA (Lampalizumab GA)

HAVEN 3 (Emicizumab in non-inh.)

17

2017

Outcome studies are event-driven: timelines may change

Outlook full year 2017

Sales

(+) Strong underlying sales momentum with good launch of new products

() Entry of first biosimilars

Core EPS

(+) PSI base effect washing out in H2 2017

() Expected lower profit growth contribution from gains on product

divestments in H2 2017

() Expected lower profit growth contribution from bond redemption and

equity securities in H2 2017

18 PSI=past service income from changes to group pension plans in 2016

2017 outlook raised

19

Group sales growth1 Mid-single digit

Core EPS growth1 Broadly in line with sales growth

Dividend outlook Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER)

20

Pharmaceuticals Division Daniel O’Day CEO Roche Pharmaceuticals

HY 2017 results

Innovation

Outlook

21

HY 2017: Pharma sales

Strong growth in US & International


HY 2017 HY 2016

CHFm CHFm CHF CER

Pharmaceuticals Division 20,521 19,460 5 5

United States 10,185 9,273 10 8

Europe 4,539 4,639 -2 0

Japan 1,771 1,756 1 0

International 4,026 3,792 6 5

Change in %

CHFm % sales

Sales 20,521 100.0

Royalties & other op. inc. 1,115 5.4

Cost of sales -4,180 -20.3

M & D -3,107 -15.1

R & D -4,383 -21.4

G & A -709 -3.5

Core operating profit 9,257 45.1

+3% in CHF

2017 vs. 2016

CER growth

HY 2017

5%

6%

2%

6%

3%

94%

19%

94%

HY 2017: Pharma Division

Core operating profit up 3%, divestments partially offsetting PSI

23 CER=Constant Exchange Rates, PSI=Past Service Income

Admin +3%

HY 2017: Launches driving strong sales growth

24 Absolute values and growth rates at Constant Exchange Rates (CER)

-250 -125 0 125 250

Tarceva

Tamiflu

Pegasys

Avastin

Lucentis

Esbriet

Activase/TNKase

Alecensa

Herceptin

Actemra/RoActemra

Xolair

MabThera/Rituxan

Perjeta

Ocrevus

Tecentriq

US

Europe

Japan

International-17%

>500%

+17%

+3%

+17%

+13%

+103%

+3%

-12%

-35%

+16%

CHFm

-1%

+2%

+13%

n/a

0 2 4 6

Cotellic +

Zelboraf

Alecensa

Tecentriq

Tarceva

CD20

Avastin

HER2

Perjeta

Herceptin

Kadcyla

+6%

-1%

-17%

>+500%

+4%

Gazyva/Gazyvaro

Cotellic

MabThera/Rituxan

(Oncology)

-12%

+103%

25

HY 2017: Oncology with +4% growth

CHFbn

YoY CER growth

HY 2017 Oncology sales: CHF 13.0bn; CER growth +4%; CER=Constant Exchange Rates; CIT=cancer immunotherapy; FL=follicular lymphoma;

NCCN=national comprehensive cancer network; CHMP=committee for medicinal products for human use

• Increased competition

• Breast cancer reimbursement in France, CIT competition

• Perjeta: Strong growth in all regions

• Kadcyla: Strong growth in US, EU and International

• US: Cotellic+Zelboraf stable 1/2L market share

• EU: Cotellic+Zelboraf increasing; Zelboraf mono declining

• US: 2L market share exceeding 50%

• US: NCCN category 1 listing in 1L as preferred option

• US: bladder: 1L cis- ineligible growing market share

• US: 2/3L lung (all-comers label) growing market share

• EU: Positive CHMP opinion in lung (2/3L) and bladder

• Gazyva in R/R FL (GADOLIN) off to a good start

• Gazyva in 1L FL (GALLIUM) on NCCN guidelines

• EU: Positive CHMP opinion in 1L FL

HER2 franchise: Good growth across all brands

26

0

500

1,000

1,500

2,000

2,500

3,000

Q2 14 Q2 15 Q2 16 Q2 17

Herceptin Perjeta Kadcyla

+23%

YoY CER growth

+11%

+19%

CER=Constant Exchange Rates; BC=breast cancer; SC=subcutaneous

CHFm

+7%

HER2 franchise Q2 2017

• Perjeta (+16%): Strong demand driven

by all regions

• Herceptin (+4%): Volume growth in EU

and US due to longer treatment

• Kadcyla (+7%): Growth in US, EU and

International

Outlook 2017

• US/EU filing of APHINITY (adj. BC)

• Herceptin: Further SC conversion

• Perjeta: Further increasing penetration in

1L and neoadjuvant

Avastin: International growth partly offsets

decline in developed markets


0

400

800

1,200

1,600

2,000

Q2 14 Q2 15 Q2 16 Q2 17

US Europe International Japan

YoY CER growth

0% +4% +13% +4%

CHFm Avastin Q2 2017

• US (-3%): Competition in lung from

cancer immunotherapies

• EU (-7%): Delisting of breast cancer

indication in France

• International (+15%): Growth mainly

driven by China

Outlook 2017

• Continued uptake in ovarian cancer

• Ph III (IMpower150) results in 1L

lung for Tecentriq+Avastin+chemo

expected in Q3/4

Immunology: Differentiation and new indications

contributing to good growth

28

0

400

800

1,200

1,600

2,000

Q2 14 Q2 15 Q2 16 Q2 17

MabThera/Rituxan (RA) Actemra IVActemra SC XolairCellCept PulmozymeEsbriet Other

CHFm

CER=Constant Exchange Rates; CHMP=committee for medicinal products for human use; CRS=cytokine release syndrom

YoY CER growth

+11%

+26%

+12%

+8%

Immunology Q2 2017

Xolair (+13%)

• Allergic asthma & chronic idiopathic

urticaria driving growth

• Asthma: US pediatrics launch ongoing;

only biologic approved for children

Actemra (+12%)

• US approval in giant cell arteritis

achieved; Positive CHMP opinion

• US: Filed for severe/life threatening CRS

• Increasing 1L monotherapy leadership

MabThera/Rituxan (+6%)

• Continues to grow in rheumatoid arthritis

and vasculitis (GPA and MPA)

Esbriet: Continuing to target mild to moderate

patient populations

29

CHFm

0

50

100

150

200

250

Q2 14 Q2 15 Q2 16 Q2 17

US Europe International

YoY CER growth

+19%

+24%

+336%

CER=Constant Exchange Rates

+150%

Esbriet Q2 2017

• US (+20%) / EU (+13%): Growth driven

by penetration into moderate and mild

patient segments

• Market leadership in US and EU5

• Penetration into mild patient segment

increasing, but slower than expected

Outlook 2017

• Increased investments in patient

education about urgency to treat

• More convenient tablet formulation

launched

Ocrevus launch off to a good start

Gaining ground in RMS and PPMS

30

• Strong launch in RMS and PPMS partly driven by patient bolus

• Initial market research indicates inroads in all treatment lines in RMS

• EU launch preparations on track

MS market shares1 MS competitive landscape

1 Source: Evaluate Pharma Multiples Sclerosis report, July 2017, data from full year 2016. Note: Market shares based on value (sales); 2 ABCR’s refers to

Avonex®, Betaferon® / Betaseron®, Copaxone®, Rebir®, Extavia®, Plegridy®; RMS=relapsing forms of multiple sclerosis; PPMS=primary progressive

multiple sclerosis

Tecfidera®19.0%

Aubagio® 6.9%

Gilenya® 14.9%

Tysabri® 9.4%

Lemtrada®2.3%

Zinbryta® 0.1%

ABCRs² 48%

Source: Adapted from Hauser SL, et al. Ann. Neurol. 2013;74(3):317-327

HY 2017 results

Innovation

Outlook

31

32

APHINITY: Perjeta+Herceptin in HER2+ eBC

Advancing care in a curative setting

von Minckwitz et al, ASCO 2017; eBC=early breast cancer (adjuvant setting); HR=hormone receptor; * Target population for

Herceptin in adjuvant breast cancer (US & EU5); current Herceptin penetration ~95%; Source: Datamonitor and internal estimates

0.8

0.6

0.4

0.2

0.0

1.0

0.8

0.6

0.4

0.2

0.0

1.0

• Risk of recurrence or death reduced by 19% in all patients, 23% in node+ and 24% in HR- patients

• Global filings ongoing

• SC co-formulation of Herceptin + Perjeta in development

Node+ subgroup

(n=3005)

HR- subgroup

(n=1722)

Perjeta+

Herceptin

(n = 1503)

Herceptin

(n = 1502)

Events, n (%) 139 (9.2) 181 (12.1)

Unstratified

HR (95% CI) 0.77 (0.62, 0.96)

p value 0.0188

0 6 12 18 24 30 36 42 48

Time (months)

90.2%

92.0%

86.7%

89.9%

Pro

po

rtio

n e

ve

nt-

fre

e

93.7%

94.9%

98.2%

98.1%

91.2%

92.8%

88.7%

91.0%

Perjeta+

Herceptin

(n = 864)

Herceptin

(n = 858)

Events, n (%) 71 (8.2) 91 (10.6)

Unstratified

HR (95% CI) 0.76 (0.56, 1.04)

p value 0.0847

93.7%

96.2%

97.9%

98.1%

Pro

po

rtio

n e

ve

nt-

fre

e

Time (months)

0 6 12 18 24 30 36 42 48

~75% of HER2+

eBC patients are

high risk*

33

ALEX: Alecensa in 1L ALK+ NSCLC

Recommended as 1L choice in NCCN guidelines

• Compared to crizotinib, Alecensa significantly prolonged PFS, delayed time to CNS progression,

improved intracranial ORR and DOR and had a more favorable safety profile

• NCCN guidelines recommend 1L use (as category 1 preferred option)

• 1L filing completed in the EU and submitted in US

Cumulative incidence

of CNS progression PFS* (ITT)

Shaw A. et al, ASCO 2017; *Investigator assessment; Alecensa (alectinib) in collaboration with Chugai; ITT=intent to treat; CNS=central

nervous system; HR=hazard ratio; PFS=progression free survival; ORR=overall response rate; DOR=duration of response;

NCCN=National Comprehensive Cancer Network; BTD=breakthrough therapy designation

0

20

40

60 Alecensa

100

1 3 6 9 12 15 18 21 24 27 30

crizotinib

Months

151 132 104 84 65 46 35 16 5

152 135 113 109 97 81 67 35 15 3

C

A

At Risk

80

PFS

(%

)

HR (95% CI)

0.47 (0.34-0.65)

p<0.0001

NE

(17.7m-NE)

11.1m

(9.1m-13.1m)

34

CEA-TCB+Tecentriq in mCRC

Next-generation CIT to further expand benefit

Tabernero J, et al. ASCO 2017, abstract #3002; * Source: Datamonitor and internal estimates, US & EU5, equals target population;

TCB=T cell bispecific; CRC=colorectal cancer; CIT=cancer immuno therapy

• Encouraging anti-tumor activity and manageable safety in heavily pretreated patients with MSS mCRC

• CEA-TCB is the first T-cell engaging therapy to show activity in solid tumors

• Pivotal development program to be initiated

CEA-TCB + Tecentriq in 3L mCRC

Pancreas

1L: 57k*

Gastric

1L: 59k*

NSCLC

adeno

1L: 76k*

= CEAhigh patients

Colorectal

1L: 149k*

91% 74% 64% 64% 29%

Breast

1L: 130k*

35

IMvigor211: Tecentriq in prior platinum mUBC

Confirmed as important treatment option

Ph2 comparison OS OS (all patients; n=931)

• Primary endpoint OS in the IC2/3 population (n=234) not met; delayed curve separation in mOS does not

fully reflect the total benefit

• Meaningful improvement in median duration of response (21.7m vs 7.4m), long remissions

• OS results highly consistent with Phase II results (IMvigor210) confirming durability of response

Powles T, et al. EACR-AACR-SIC 2017; mUBC=metastatic urothelial bladder cancer; OS=overall survival; HR=hazard ratio;

CHMP=committee for medicinal products for human use; NSCLC=non-small cell lung cancer

36

IMvigor211: Tecentriq in prior platinum mUBC

Confirmed as important treatment option

• Improved OS with Tecentriq vs taxanes (HR=0.73), but not versus vinflunine (HR=0.97)

• No new safety signals and more favorable safety profile for Tecentriq than for chemotherapy

• Positive CHMP opinion (1L cisplatin ineligible mUBC; prior platinum mUBC; 2/3L NSCLC) obtained

Powles T, et al. EACR-AACR-SIC 2017; mUBC=metastatic urothelial bladder cancer; OS=overall survival; HR=hazard ratio;

CHMP=committee for medicinal products for human use; NSCLC=non-small cell lung cancer

All patients with taxane Treatment related adverse events

No. at Risk

Atezolizumab 215 186 153 125 106 89 81 66 45 34 19 7 0

Taxane 214 179 147 122 94 74 58 35 20 16 4 3 1

80

60

0

10 12 14 16 18 20 2 4 6 8 0 24 22

20

40

Ove

rall S

urv

iva

l

100

Months

HR (95% CI)

0.73 (0.58, 0.92)

8.3m

6.6, 9.8)

7.5m

(6.7, 8.6)

Tecentriq

taxane

No. at Risk

Atezolizumab 252 219 174 155 139 112 96 72 45 25 15 6 1

Vinflunine 250 218 183 146 125 101 82 64 20 26 13 4 0

80

60

0

10 12 14 16 18 20 2 4 6 8 0 24 22

20

40

Ove

rall S

urv

iva

l

100

Months

HR (95% CI)

0.97 (0.78, 1.19)

9.2m

(7.9, 10.4)

8.3m

(6.9, 9.6)

Tecentriq

vinflunine

Chemotherapy Tecentriq

HAVEN 1 intra-individual comparison (adults) Emicizumab vs prior BPA prophylaxis

37

• Event rate reduced by 79% with emicizumab prophylaxis vs prior BPA prophylaxis

• 70.8% of patients with zero events on emicizumab prophylaxis

• Filing in the US, EU and Japan completed

Reduction of treated bleeds

(n=24)

Number of treated bleeds

Oldenburg J, et al. ISTH 2017; ABR=annualized bleeding rate (calculated with negative binomial regression model); BPA=bypassing

agent; NIS=non-interventional study; BTD=breakthrough therapy designation

HAVEN 2 intra-individual comparison (pediatrics) Emicizumab vs prior BPA prophylaxis

38 Young G, et al. ISTH 2017; ABR=annualized bleeding rate (calculated with negative binomial regression model); BPA=bypassing

agent; NIS=non-interventional study; P=participant; BTD=breakthrough therapy designation

• Zero events for all 8 participants (P 1-8) receiving emicizumab (efficacy period 85–99 days)

• Substantial reductions in event rate with emicizumab prophylaxis vs prior BPA treatment

H1 2017 results

Innovation

Outlook

39

2017: Key late-stage news flow

Compound Indication Milestone

Regulatory

Alecensa 2L ALK+ NSCLC EU approval

Ocrevus RMS / PPMS US/EU launch

Tecentriq 1L cisplatin ineligible mUBC US approval

Tecentriq 2/3L NSCLC and 2L prior platinum mUBC EU approval

Gazyva 1L FL (iNHL) US/EU filing

Actemra Giant cell arteritis US/EU approval

emicizumab Hemophilia A inhibitors US/EU filing

Phase III

readouts*

Perjeta + Herceptin Adjuvant HER2+ BC Ph III APHINITY

Alecensa 1L ALK+ NSCLC Ph III ALEX

Venclexta + Rituxan R/R CLL Ph III MURANO

Tecentriq + chemo/

Tecentriq + chemo + Avastin 1L NSCLC Ph III IMpower150

lampalizumab Geographic atrophy Ph III SPECTRI and CHROMA

emicizumab Hemophilia A non-inhibitors Ph III HAVEN3

40 * Outcome studies are event-driven: Timelines may change; mCNV=choroidal neovascularisation secondary to myopia

Additional H1 2017 news flow:

• Lucentis: Approval in mCNV and diabetic retinopathy

• Rituxan Hycela for blood cancers approved and launched in the US

• Emicizumab: Interim results in pediatric inhibitors (HAVEN2)

• Positive CHMP opinion for Tecentriq in 1L cisplatin ineligible mUBC

41

Diagnostics Division Roland Diggelmann CEO Roche Diagnostics

HY 2017: Diagnostics Division sales

Good growth driven by Centralised and Point of Care Solutions and Tissue Diagnostics


Underlying growth of Molecular Diagnostics excluding sequencing business: +2%

HY 2017 HY 2016

CHFm CHFm CHF CER

Diagnostics Division 5,823 5,562 5 5

Centralised and Point of Care Solutions 3,456 3,233 7 8

Diabetes Care 962 998 -4 -4

Molecular Diagnostics 920 903 2 1

Tissue Diagnostics 485 428 13 13

Change in %

North America

+1%

26% of divisional sales

Latin America

+8%


Japan

+2%

4% of divisional sales EMEA1

+3%


HY 2017: Diagnostics regional sales

Growth driven by all regions

Asia Pacific

+13%


43

+16% growth in E7 countries2

1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates

HY 2017: Diagnostics Division highlights

44

• Driven by immunodiagnostics (+13%);

clinical chemistry (+3%); PoC* (+3%)

• Continued US pricing and reimbursement

pressures

• Virology (-1%); Blood screening (+3%)

• Advanced staining portfolio (+9%); primary

staining (+15%) and companion diagnostics

(+40%)

0.0 1.0 2.0 3.0 4.0

Tissue

Diagnostics

Molecular

Diagnostics

Diabetes

Care

Centralised

and Point of

Care

Solutions

EMEA

North America

RoW

+13%

-4%

+8%

+1%

CHFbn

**

* PoC =Point of Care; ** Underlying growth of Molecular Diagnostics excluding sequencing business: +2%

CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

YoY CER growth

HY 2017: Diagnostics Division

Core operating profit growth partially offset by PSI

45

CHFm % sales

Sales 5,823 100.0

Royalties & other op. inc. 89 1.5


M & D -1,337 -23.0

R & D -642 -11.0

G & A -225 -3.9


+5% in CHF

HY 2017 2017 vs. 2016

CER growth

5%

4%

5%

-1%

5%

70%

48%

70%Admin +2%

CER=Constant Exchange Rates; PSI=Past Service Income

Immunoassays contribute 1/3 of Diagnostics sales

Growing double digit > 19 years

46 CER=Constant Exchange Rates; “Other” include Needed Common Products, Allergy, Rheumatoid Arthritis, Immunosuppressants

HY 2017 Sales

12% 10%

Tumormarker

15%

Cardiac

10% 22%

Women’s

Health

Other Hormones

7%

Infectious

Diseases

Endo -

Thyroid

9%

Critical

Care

Anemia

36%

8%

Integrated workflow of cobas 8000 combined with

cobas 6800/8800

Broadest menu and superior integrated workflow

YoY CER growth

US launch of cobas e 801 and HIV assay*

Opens opportunities to gain market share

47

• 100% sensitivity to HIV-1 and recognition of all

known HIV groups and subtypes

• High specificity in samples from routine clinical,

pregnancy testing and dialysis patients

• Broadest infectious disease menu in the US

cobas e 801

*Currently the HIV combi PT is available on the cobas e 602

• Double throughput on same footprint

cobas® MRSA/SA* assay launched in CE markets

cobas® Liat® System menu expansion to meet European markets needs

* MRSA=methicillin resistant Staphylococcus Aureus; RSV=Respiratory Syncytial Virus ** In development; *** e.g. hospital emergency room, STAT lab, doctor’s office; pharmacy clinic

cobas® Liat®

assay tube

48

• Easy to use with minimal hands on time

• Lab quality performance in 30 minutes or less

• Suitable for testing in a variety of settings***

Menu of assays available and in development

cobas® Liat®

Analyzer

CE US CE US

cobas® Influenza A/B cobas® Cdiff

cobas® Strep A cobas® MRSA/SA

cobas® Influenza A/B & RSV*

cobas® Pertussis**

Market leader in Tissue Diagnostics

Superior multiplex IHC* clinical lab workflow driving double digit growth

Automated

multiplex IHC

staining

Automatic whole

slide image analysis

Result interpretation

“cold” vs. “hot tumor”

with TILs**

Whole slide scanning

(BF**, FL**)

Diagnostic

and/or treatment

decision

Spatial characterisation

of tumor

micro-environment

Patient specimen

arrives for analysis

49 * IHC = Immunohistochemistry; ** BF = brightfield; FL = fluorescent; TILs = tumor-infiltrating lymphocytes

Launch of three liquid biopsy oncology gene

panels

50 Validated on an on-market Illumina platform (Next Seq 500 and Next Seq 550). Next Seq 500/550 instruments and associated sequencing reagents are manufactured and sold by Illumina and are not supplied by Roche. * SNV – Single Nucleotide Variant; CNV – Copy number Variant; Indel – Insertion or Deletion.

• Includes all reagents & informatics for a "sample in, result out” solution

• Research Use Only

• All four mutation classes in one panel (SNV, CNV, fusions and indels)*

Three Kit Options

AVENIO ctDNA Targeted Kit

AVENIO ctDNA Expanded Kit

AVENIO ctDNA Surveillance Kit

Features

• Pan-cancer assay for tumor profiling

• 17 genes (81 kb)

• Pan-cancer assay for expanded tumor

profiling

• 77 genes (192 kb)

• Longitudinal tumor burden monitoring,

focus on lung and colorectal cancer

• 197 genes (198 kb)

Area Product Market

Instruments/

Devices

Central

Laboratory

cobas 8000 <e 801> – High throughput immunochemistry analyser

CCM High Speed – cobas connection module (CCM) for up to 6000 samples/hour

US

WW

Coagulation

Testing cobas t 511 / t 711 – Medium and high volume coagulation systems EU

Point of Care CoaguChek Vantus – Hand-held coagulation monitoring system for Patient Self-

Testing US

Diabetes Care Accu-Chek Instant bG System – Effortless, accurate and affordable bG system

for price sensitive markets EU

Tests/

Assays

HPV cobas HPV – Next generation HPV DNA test leveraging 68/8800 Automation to detect

14 hrHPV with simultaneous detection of genotypes 16 and 18

CINtec Histology – Diagnostic component of the Roche Cervical Cancer portfolio

EU

US

Virology cobas HIV 1&2 Qual – For use on the cobas 6800/8800 Systems; for diagnosis of acute

HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection EU

Sequencing AVENIO ctDNA panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted

panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)

EU/US

cobas Liat

cobas Liat C.diff – Qualitative IVD test, that utilizes real-time PCR, for the direct

detection of the tcdB gene of toxigenic C. difficile in unformed stool specimens

cobas Liat MRSA/SA – Qualitative IVD test, that utilizes real-time PCR, for the direct

detection of MRSA and Staphylococcus aureus DNA from nasal swabs

EU

EU

Women’s Health AMH – Immunoassay for the in vitro quantitative determination of anti-Mullerian hormone

(AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics

US

Companion

Diagnostics

PD-L1 (SP142) for Bladder Cancer* – complementary diagnostic for Tecentriq

PD-L1 (SP142) for NSCLC* – complementary diagnostic for Tecentriq

EU

EU

Key launch list 2017

51 * = Achieve commercial readiness, dependent on Pharma label and approval

52

Finance Alan Hippe Chief Financial Officer

• Strong sales growth of +5%1 and Core operating profit up +3%1

• Core EPS growth +6%1

HY 2017: Highlights

53

Business

Net financial results

• Core net financial result improved by +44%1 driven by lack of debt redemption and higher

income from equity securities, in addition to 18%1 lower interest expenses2

1 At Constant Exchange Rates (CER) 2 incl. amortisation of debt discount and net gains on interest rate derivatives

• Significant cash generation (Operating Free Cash Flow of CHF 7.6bn, +37%1)

• Net debt lower by CHF 4bn vs. June 30, 2016; higher by CHF 1bn vs. YE 2016 due to

dividend payments

Cash flow

IFRS

• Net income +2%1

HY 2017 HY 2016

CHFm CHFm CHF CER

Sales 26,344 25,022 5 5

Core operating profit 10,135 9,854 3 3

as % of sales 38.5 39.4

Core net income 7,187 6,761 6 7

as % of sales 27.3 27.0

Core EPS (CHF) 8.23 7.74 6 6

IFRS net income 5,577 5,467 2 2

Operating free cash flow 7,589 5,487 38 37

as % of sales 28.8 21.9

Free cash flow 5,605 2,849 97 95

as % of sales 21.3 11.4

Change in %

HY 2017: Group performance

Core EPS growth ahead of sales


HY 2017: Group operating performance

Core operating profit growth +3%


CHFm % sales

Sales 26,344 100.0



M & D -4,444 -16.9

R & D -5,025 -19.1

G & A -1,115 -4.2


+3% in CHF

HY 2017 2017 vs. 2016

CER growth

5%

5%

3%

5%

3%

75%

21%

75%

CHFm % sales

Sales 26,344 100.0



M & D -4,444 -16.9

R & D -5,025 -19.1

G & A -1,115 -4.2


+3% in CHF

HY 2017 2017 vs. 2016

CER growth

5%

5%

3%

5%

3%

75%

21%

75%

2017 vs. 2016

CER growth

Admin +3%

9,2368,392

1,021

9,8548,984

1,007

10,1359,257

1,059

Roche Group Pharma Division Diagnostics Division

2015 2016 2017

39.2% 39.4% 38.5%

45.7% 46.2% 45.1%

19.5% 18.1% 18.2%

HY 2017: Core operating profit and margin

Higher gains on product divestments partially offsetting PSI

56

CHFm

-0.8%p1

+0.1%p1

-0.9%p1

+5%1

+3%1 +3%1

% of sales

1 At CER=Constant Exchange Rates; PSI=past service income

-596

-496 -334

+100

+64

+53 +37 +8

Equity securities

Debt Redemption

HY 2016

HY 2017

FX G/L All other, net

Interest expenses1

CHFm

• Net financial result improved by +44% at CER

• Interest expenses1 down by +18% at CER

CER=Constant Exchange Rates 1 incl. amortisation of debt discount and net gains on interest rate derivatives

HY 2017: Core net financial result

Significant improvement +44%

57

27.0 26.7

-0.3

HY 2016 Profit mix and other HY 2017

HY 2017: Group Core tax rate

58

Figures in %

Half Year 2017 2016 2017 CHFm CHF CER

Core operating profit 9,854 10,135 +281 +3% +3%

Global restructuring plans -391 -321 +70

Amortisation of intangible assets -896 -906 -10

Impairment of intangible assets1 -377 -1,475 -1,098

Alliances & Business Combinations -21 +197 +218

Legal & Environmental -27 +165 +192

Total non-core operating items -1,712 -2,340 -628

IFRS operating profit 8,142 7,795 -347 -4% -4%

Total financial result & taxes -2,675 -2,218 +457

IFRS net income 5,467 5,577 +110 +2% +2%

CER=Constant Exchange Rates; 1 incl. goodwill

HY 2017: Non-core items; IFRS result impacted

by impairments of intangible assets

59

6,525 6,645

146

5,4875,937

-183

7,589 7,560

260

Roche Group Pharma Division Diagnostics Division

2015 2016

2016

27.7%21.9%

28.8%

36.2%30.5%

36.8%

2.8%-3.3%

4.5%

2017

HY 2017: Strong operating free cash flow and

margin

60

CHFm

+6.7%p1

n.a.

+6.2%p1

n.a.

+26%1 +37%1

1 At CER=Constant Exchange Rates

% of sales

+5,487

+7,589

+844

+1,039

+121 +98

Investment in PP&E

OP net of cash adjustments

HY 2017: Operating Free Cash Flow

CHF +2bn / +37% higher than PY

61

HY 2016

HY 2017

Investment in IA

NWC movement

CHFm

OFCF improved by +37%/+2,046m at CER

CER=Constant Exchange Rates; OP=operating profit; NWC=net working capital; PP&E=property, plant & equipment;

IA=intangible assets

-13.2

+7.6

-6.6

-14.2 -2.0

Treasury -0.4

Taxes -1.6

CHFbn

HY 2017: Group net debt development

Higher net debt due to dividend payment, partially offset by FCF

62

0

Net debt

31 Dec 2016

Operating Free

Cash Flow

Dividends & others

Net debt

30 Jun 2017

Non-op. FCF

Free Cash Flow CHF 5.6bn

vs. 2.8bn in 2016

Dividends -7.1

Currency

Translation, +0.5

Others

CER=Constant Exchange Rates

[PY: -18.3] [PY: +5.5]

Balance sheet: Net debt to total assets

63

Net debt

(CHFbn)

Total assets

(CHFbn)

Net debt /

total assets

17.314.1

18.313.2 14.2

68.9

75.8 74.5 76.871.8

30 Jun 2015 31 Dec 2015 30 Jun 2016 31 Dec 2016 30 Jun 2017

25%

19%

25%

17%20%

20%

Net debt/

total assets:

Assets Equity & liabilities

48.1 45.2

26.4 25.3

19.6 19.7

27.8 25.9

9.1 6.922.6 20.6

31 Dec

2016

30 Jun

2017

31 Dec

2016

30 Jun

2017

71.8 71.8-3%

-23%

+4%

-3%

Current

liabilities

Non-current

liabilities

Equity

(Net assets)

12% 10%

25%

63%

27%

34% 35%

76.8 76.8

Current

liabilities

63%

30%

36%

29%

36%

-5%

% change in CER

vs 31 Dec 2016

-3%

-4%

-2%

Cash and

marketable

securities

Other

current

assets

Non-current

assets

CHFbn% change in CER

vs 31 Dec 2016

Balance sheet 30 June 2017

Net debt to total assets at 20%

CER=Constant Exchange Rates 64

CER

sales

growth

HY 2017

vs.

HY 2016

Exchange rate impact on sales growth

Slight positive impact from USD and Lat-Am currencies, partly offset by other Europe and EUR


+5.0% +5.3%

+0.6p +0.3p +0.2p +0.1p 0.0p -0.4p

-0.5p

CER USD Lat-Am Other JPY As-Pac EUR Other

Europe

CHF

CHF

sales

growth

HY 2017

vs.

HY 2016

1.01 1.00 1.00 1.00 0.99 0.97 0.96 0.96 0.96 0.96 0.96 0.96

1.00 0.99

0.98

0.98 0.99

0.98 0.98

0.99

J F M A M J J A S O N D

Low currency impact expected in 2017

66

Assuming the 30 June 2017 exchange rates

remain stable until end of 2017,

2017 impact is expected to be (%p):

CHF / USD

CHF / EUR

+1%

Average YTD 2016

1% 1% 0% -1%

-2% -2% -1% 0%

Assumed

average YTD

2017

Monthly avg fx rates 2017 Fx rates at 30 Jun 2017 Q1 HY Sep

YTD

FY

Sales 0 0

Core

operating

profit

0

Core EPS 0

1.07 1.07 1.07 1.07 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09

1.07 1.08 1.08 1.08

1.10 1.10 1.09 1.09

J F M A M J J A S O N D

2017 outlook raised

67

Group sales growth1 Mid-single digit

Core EPS growth1 Broadly in line with sales growth

Dividend outlook Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER)

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group HY 2017 results

Diagnostics

Foreign exchange rate information 68

New to phase I New to phase II New to phase III New to registration

Changes to the development pipeline

HY 2017 update

Removed from phase I Removed from phase II Removed from phase III Removed from registration

1 NME: RG7835 – autoimmune diseases

3 AIs: RG7421 Cotellic + Tecentriq – 2L

BRAF WT mM

RG7446 Tecentriq + rucaparib –

ovarian cancer

RG7446 Tecentriq-based Morpheus

platform – pancreatic cancer

4 NMEs: RG6061 HIF1 alpha LNA – solid

tumors

RG6078 IDO inh – solid tumors

RG7888 OX40 MAb – solid tumors

RG6016 LSD1 inh - SCLC

4 AIs: RG3616 Erivedge + Esbriet - IPF

RG6078 IDO inh + Tecentriq – solid

tumors

RG7159 obinutuzumab – renal

transplant

RG7888 OX40 MAb + Tecentriq –

solid tumors

1 NME in-licensed from BMS: RG6206 anti-myostatin adnectin – DMD

1 NME transitioned from Ph1: RG7935 α-synuclein MAb – Parkinson’s

1 NME following filing in EU/US: RG6013 emicizumab – hemophilia A

FVIII inh (pediatrics and adults)

1 AI following EU approval: RG435 Avastin – rel. ovarian ca. Pt-

sensitive

1 AI following US approval: RG105 Rituxan Hycela™ (SC) -

NHL/CLL

1 NME transitioned from Ph2: RG7440 ipatasertib – CRPC

1 AI: RG7446 Tecentriq + Abraxane – TNBC

neoadj

1 NME: CHU nemolizumab - atopic dermatitis

(out-licensed)

69

Status as of July 27, 2017

RG6026 CD20 TCB heme tumors

RG6047 SERD (2) ER+ (HER2-neg) mBC

RG6058 TIGIT ± Tecentriq solid tumors

RG6114 mPI3K alpha inh HR+ BC

RG6146 BET inh solid + heme tumors

RG6180 personalized cancer vaccine oncology

RG6185 pan-RAF inh + Cotellic solid tumors

RG7155 emactuzumab + Tecentriq solid tumors

emactuzumab + CD40 iMAb solid tumors

RG7159 anti-CD20 multiple combos heme tumors

RG7386 FAP-DR5 biMAb solid tumors

RG7421 Cotellic + Zelboraf + T melanoma

Cotellic + T 2L BRAF WT mM

RG7446

Tecentriq solid tumors

Tecentriq NMIBC

T-based Morpheus platform pancreatic ca

T + Avastin + Cotellic 2/3L CRC

T ± Avastin ± chemo HCC, GC, PaC

T ± Avastin ± chemo solid tumors

T + Cotellic solid tumors

T + ipi/IFN solid tumors

T + Tarceva/Alecensa NSCLC

T + anti-CD20 multiple combos lymphoma

T ± lenalidomide ± daratumumab MM

T + K/HP HER2+ BC

T + HMA MDS

T + radium 223 mCRPC

T + guadecitabine AML

T + rucaparib ovarian ca

RG7461 FAP IL2v FP + Tecentriq ± Avastin RCC

RG7601 Venclexta + Cotellic/idasanutlin AML

Venclexta ± azacitidine r/r MDS

RG7741 ChK1 inh solid tumors

RG7802 CEA TCB ± Tecentriq solid tumors

RG7813 CEA IL2v FP* + Tecentriq solid tumors


RG7876 CD40 iMAb + Tecentriq solid tumors

CD40 iMAb + vanucizumab solid tumors

RG7882 MUC16 ADC ovarian ca

RG7986 ADC r/r NHL

CHU Raf/MEK dual inh solid tumors

CHU glypican-3/CD3 biMAb solid tumors

RG3616 Erivedge + ruxolitinib myelofibrosis

RG6069 anti-fibrotic agent fibrosis

RG6107 C5 inh MAb PNH

RG7835 - autoimmune diseases

RG7880 IL-22Fc inflammatory diseases

RG7990 - asthma

RG6004 HBV LNA HBV

RG6080 nacubactam (DBO β-lactamase inh) bact.infections

RG7854 TLR7 agonist (3) HBV

RG7861 anti-S. aureus TAC infectious diseases

RG7907 HBV Capsid (2) HBV

RG7992 FGFR1/KLB MAb metabolic diseases

RG6000 - ALS

RG6029 Nav1.7 inh (2) pain

RG6100 Tau MAb Alzheimer’s

RG7203 PDE10A inh schizophrenia

RG7906 - psychiatric disorders

IONIS ASO Huntington’s

CHU PTH1 recep. ago hypoparathyroidism

CHU - Hyperphosphatemia

RG3502 Kadcyla + Tecentriq 2L HER2+ mBC

RG7221 vanucizumab mCRC

RG7421 Cotellic + Tecentriq ± taxane TNBC

RG7440 ipatasertib 1L TNBC

ipatasertib TNBC neoadj

RG7596 polatuzumab vedotin 1L DLBCL

RG7601

Venclexta + Rituxan DLBCL

Venclexta + Rituxan r/r FL

Venclexta + azacitidine 1L MDS

RG7604 taselisib + letrozole (HER2-neg) BC neoadj

RG7686 codrituzumab liver cancer

RG3637 lebrikizumab atopic dermatitis

lebrikizumab ± Esbriet IPF

RG6125 Cadherin-11 MAb RA

RG6149 ST2 MAb asthma

RG7159 obinutuzumab lupus

RG7625 Cat-S antag autoimmune diseases

RG7845 BTK inh RA, lupus, CSU

CHU nemolizumab** pruritus in dialysis patients

PRO VAP-1 inh inflammatory disease

NOV TLR4 MAb autoimmune diseases

RG6152 CAP endonuclease inh influenza

RG7745 Flu A MAb influenza A

CHU URAT1 inh gout

RG1662 basmisanil CIAS, post-stroke recovery

RG6083 olesoxime SMA

RG6206 anti-myostatin adnectin DMD

RG7314 V1a receptor antag autism

RG7916 SMN2 splicer(2) SMA

RG7935 α-synuclein MAb Parkinson's

RG3645 ranibizumab PDS wAMD

RG7716 VEGF-ANG2 biMAb wAMD, DME

70

New Molecular Entity (NME) RG-No Roche/Genentech

Additional Indication (AI) CHU Chugai managed

Oncology IONIS IONIS managed

Immunology PRO Proximagen managed

Infectious Diseases NOV Novimmune managed

CardioMetabolism *INN: cergutuzumab amunaleukin

Neuroscience **out-licensed to Galderma and Maruho

for atopic dermatitis Ophthalmology

Other T=Tecentriq; TCB=T cell bispecific

Phase I (38 NMEs + 24 AIs)


Phase II (21 NMEs + 11 AIs)

Roche Group development pipeline

RG1273 Perjeta + Herceptin HER2+ BC adj

Perjeta + Herceptin 1L HER2+ gastric ca

RG3502 Kadcyla HER2+ BC adj

Kadcyla + Perjeta HER2+ BC adj

RG6013 emicizumab hemophilia A w/o FVIII inh

emicizumab Q4W hemophilia A

RG7204 Zelboraf BRAFm melanoma adj

RG7388 idasanutlin AML

RG7440 ipatasertib CRPC

RG7421 Cotellic + Zelboraf +T BRAFm melanoma

RG7446

Tecentriq NSCLC adj

Tecentriq MIBC adj

Tecentriq Dx+ 1L sq + non-sq SCLC

Tecentriq RCC adj

T + Abraxane 1L non-sq NSCLC

T + chemo + Avastin 1L ovarian cancer

T + chemo + Avastin 1L non-sq NSCLC

T + chemo + pemetrexed 1L non-sq NSCLC

T + Abraxane 1L sq NSCLC

T + Abraxane 1L TNBC

T + Abraxane TNBC neoadj

T + Avastin RCC

T + Cotellic 3L CRC

T ± chemo 1L mUC

T + chemo 1L extensive stage SCLC

T + enzalutamide CRPC

RG7601

Venclexta + Rituxan r/r CLL

Venclexta + Gazyva 1L CLL

Venclexta + bortezomib MM

Venclexta + HMA 1L AML

RG7604 taselisib + fulvestrant ER+(HER2-neg) mBC

RG105 MabThera pemphigus vulgaris

RG1569 Actemra systemic sclerosis

RG7413 etrolizumab ulcerative colitis

etrolizumab Crohn’s

RG1450 gantenerumab Alzheimer’s

RG6168 IL-6R Mab (SA237) neuromyelitis optica

RG7412 crenezumab Alzheimer’s

RG7417 lampalizumab geographic atrophy

RG3645 Lucentis 0,3mg PFS1 DME/DR

RG435 Avastin1 GBM

RG6013 emicizumab hemophilia A FVIII inh

RG7159 Gazyva2 1L FL

RG7446 Tecentriq2,3 2L mUC

Tecentriq2,4 2L+ NSCLC

RG7853 Alecensa 1L ALK+ NSCLC

RG1569 Actemra2,4 giant cell arteritis

CHU Actemra large-vessel vasculitis

RG1594 OCREVUS®4 PPMS + RMS


71

1 US only

2

3

Positive CHMP opinion

Filing based on IMvigor210; accelerated approval

in US for 1L & 2L; phase III completed

4 Approved in US

Phase III (8 NMEs + 32 AIs) Registration (3 NMEs + 6 AIs)




Oncology RG1569 Branded as RoActemra (EU)

Immunology RG7159 Branded as Gazyvaro (EU)

Infectious Diseases

CardioMetabolism

Neuroscience

Ophthalmology

Other T=Tecentriq; TCB=T cell bispecific

NME submissions and their additional indications

Projects currently in phase II and III

72

RG6013 Emicizumab ✓

hemophilia A FVIII inh

pediatrics and adults

RG7417 lampalizumab

geographic atrophy

RG6168 IL-6R MAb SA237 neuromyelitis optica

RG7604 taselisib+fulvestrant

PIK3CAmut ER+ (HER2-neg) mBC

RG6013

emicizumab hemophilia A FVIII non-inh

RG6013 emicizumab

hemophilia A, Q4W

RG7440 ipatasertib

CRPC

RG7440 ipatasertib

1L TNBC

RG7440 ipatasertib

TNBC neoadj

RG7596

polatuzumab vedotin

1L DLBCL

RG7604 taselisib + letrozole

ER+ (HER2-neg) BC neoadj

RG7716 VEGF/ANG2 biMAb

wAMD/DME

RG1450 gantenerumab

Alzheimer‘s

RG1662

basmisanil CIAS, post-stroke

recovery

RG6083 olesoxime

SMA

RG6206

anti-myostatin adnectin

DMD

RG7314 V1 receptor antag

autism

RG7412 crenezumab Alzheimer’s

RG7916 SMN2 splicer(2)

SMA

RG7935 α-synuclein MAb

Parkinson’s

RG6152

CAP endonuclease inh

influenza

RG7745 Flu A MAb influenza

RG3637 lebrikizumab

atopic dermatitis

RG3637

lebrikizumab ± Esbriet

IPF

RG6125 Cadherin-11 MAb

RA

RG6149 ST2 MAb Asthma

RG7413 etrolizumab

ulcerative colitis

RG7413 etrolizumab

Crohn’s

RG7625 Cat S antag

autoimmune diseases

RG7845 BTK inh

autoimmune diseases

2018 2017 2020 and beyond 2019

RG7388 idasanutlin

AML

New Molecular Entity (NME) CardioMetabolism

Additional Indication (AI) Neuroscience

Oncology Ophthalmology

Immunology Other

Infectious Diseases

✓ Indicates a submission which has occurred with regulatory action pending

Unless stated otherwise submissions are planned to occur in US and EU


AI submissions for existing products

Projects currently in phase II and III

73

✓ Indicates submission to health authorities has occurred

Unless stated otherwise submissions are planned to occur in US and EU

2018 2017 2020 and beyond 2019

RG3645

Lucentis 0.3mg PFS (US)

DME/DR

RG435 Avastin (US) ✓

GBM

RG1273

Perjeta + Herceptin 1L HER2+

gastric cancer

RG1273 Perjeta + Herceptin

HER2+ BC adj.

RG7159 Gazyva (US) ✓

1L FL

RG7204 Zelboraf

BRAFmut melanoma adj.

RG7601 Venclexta + Rituxan

r/r CLL

RG7853 Alecensa ✓

1L ALK+ NSCLC

RG105 MabThera

pemphigus vulgaris

RG1569 Actemra

systemic sclerosis

RG7446

Tecentriq + chemo + Avastin

1L non-sq NSCLC

RG7446 Tecentriq + Abraxane

1L sq NSCLC


1L non-sq NSCLC

RG7446 Tecentriq + chemo

1L extens. stage SCLC

RG7446 Tecentriq + Avastin

RCC


1L TNBC

RG3502 Kadcyla + Tecentriq

2L Her2+ mBC

RG3502 Kadcyla + Perjeta

HER2+ BC adj.

RG3502 Kadcyla

HER2+ BC adj.


r/r FL


DLBCL

RG7601 Venclexta + HMA

1L AML

RG7601 Venclexta + HMA

1L MDS

RG7421

Cotellic + Tecentriq ± taxane

TNBC

RG3645 ranibizumab PDS

wAMD

RG7159 obinutuzumab

lupus nephritis

RG7446

Tecentriq + Abraxane TNBC neoadj

RG7446 Tecentriq ± chemo

1L mUC

RG7446 Tecentriq NSCLC adj

RG7446 Tecentriq MIBC adj

RG7446

Tecentriq + enzalutamide

CRPC

RG7446 Tecentriq RCC adj

RG7446

Tecentriq + chemo + Avastin

1L ovarian cancer




Immunology Other

Infectious Diseases

RG7446 Tecentriq + Cotellic

3L CRC

RG7421

Cotellic + Tecentriq + Zelboraf

BRAFmut melanoma

RG7446

Tecentriq 1L non-sq + sq NSCLC (Dx+)

RG7446

Tecentriq + chemo + pemetrexed

1L non-sq NSCLC

RG7601 Venclexta + Gazyva

1L CLL

RG7601

Venclexta + bortezomib

MM


EU Japan-Chugai US

Major granted and pending approvals 2017

74

RG105

Rituxan Hycela™ (SC)

NHL/CLL

June 2017

RG7446

Tecentriq 1L bladder cancer, cis-ineligible

April 2017

RG1569

Actemra giant cell arteritis

May 2017

RG1594

OCREVUS®

PPMS & RMS

March 2017

RG3645

Lucentis mCNV

January 2017

RG3645

Lucentis diabetic retinopathy w/o DME

April 2017

RG435

Avastin GBM

Filed February 2017

RG6013

emicizumab hemophilia A FVIII inh (pediatrics and adults)

Filed June 2017

RG7853

Alecensa 1L ALK+ NSCLC Filed May 2017

RG7159

Gazyva

follicular lymphoma 1L

Filed June 2017

RG6013


Filed June 2017

RG7853

Alecensa

1L ALK+ NSCLC

Filed March 2017

RG7446

Tecentriq

mUC 2L

Filed April 2016

RG7446

Tecentriq

2L+ NSCLC

Filed April 2016

RG7159

Gazyva

1L follicular lymphoma

Filed October 2016

RG1594

OCREVUS®

PPMS & RMS

Filed April 2016

RG1569

Actemra

giant cell arteritis

Filed November 2016

Approved

Pending Approval

RG6013


Filed July 2017

RG7446

Tecentriq

2L+ NSCLC

Filed February 2017

CHU

Actemra

large-vessel vasculitis

Filed November 2016

RG7853

Alecensa

2L ALK+ NSCLC

February 2017

RG435

Avastin

chemo backbone extension

rel. OC Pt-sensitive

June 2017




Immunology Other

Infectious Diseases



Combinations




RG7159 anti-CD20 multiple combos heme tumors


Cotellic + T BRAF WT mM2L

RG7446


T + Cotellic ± Avastin 2/3L CRC








T + K/HP HER2+ BC

T + HMA MDS





RG7601

RG7601

Venclexta + Cotellic/idasanutlin AML

Venclexta ± azacitidine r/r MDS





RG3616 Erivedge + ruxolitinib myelofibrosis

Phase I (6 NMEs + 22 AIs)



RG7601

Venclexta + Rituxan DLBCL

Venclexta + Rituxan r/r FL

Venclexta + azacitidine 1L MDS

RG7604 taselisib + letrozole (HER2-) BC neoadj

RG3637 lebrikizumab ± Esbriet IPF

Phase II (7 AIs)

RG1273 Perjeta + Herceptin HER2+ BC adj

Perjeta + Herceptin 1L HER2+ gastric ca

RG3502 Kadcyla + Perjeta HER2+ BC adj

RG7421 Cotellic + Zelboraf + T BRAFm melanoma

RG7446








T + Cotellic 3L CRC

T + Avastin RCC

T ± chemo 1L mUC

T + chemo 1L extens. stage SCLC


RG7601

Venclexta + Rituxan r/r CLL

Venclexta + Gazyva 1L CLL

Venclexta + bortezomib MM

Venclexta + HMA 1L AML

RG7604 taselisib + fulvestrant ER+ (HER2-neg) mBC

Phase III (1 NME + 20 AIs)



Oncology *INN: cergutuzumab amunaleukin

Immunology T=Tecentriq; TCB=T cell bispecific 75


Cancer immunotherapy pipeline overview

RG6026 CD20 TCB hematopoietic tumors


RG6180 personalized cancer vaccine oncology




Cotellic + T BRAF WT mM2L

RG7446

Tecentriq solid tumors

Tecentriq NMIBC


T + Cotellic ± Avastin 2/3L CRC








T + K/HP HER2+ BC

T + HMA MDS












IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma

SNDX** Tecentriq + entinostat TNBC

RG7446 Tecentriq1 2L mUC

Tecentriq2 2L+ NSCLC

RG7421 Cotellic + Zelboraf + T BRAFm melanoma

RG7446

Tecentriq NSCLC adj

Tecentriq MIBC adj

Tecentriq Dx+ 1L sq + non-sq SCLC

Tecentriq RCC adj








T + Avastin RCC

T + Cotellic 3L CRC

T ± chemo 1L mUC

T + chemo 1L extensive stage SCLC


1 Filing based on IMvigor210, accelerated approval in US

for 1L & 2L; positive CHMP opinion, phase III completed

2 Approved in US, positive CHMP opinion ** External collaborations: INCY- Incyte IDO inh; CLDX - Celldex CD27 MAb; CRVS – Corvus ADORA2A antag; KITE – Kite KTE-C19; AMGN – Amgen oncolytic virus; JNJ – Janssen CD38 MAb; CLVS – Clovis PARP inh; EPZM – Epizyme EZH2 inh; BLRX - BioLine Rx CXCR4 antag; IMDZ – Immune Design CMB305; SNDX – Syndax HDAC inh


Additional Indication (AI) *INN: cergutuzumab amunaleukin

Oncology T=Tecentriq; TCB=T cell bispecific

76

RG7446

T + Cotellic pancreatic ca

T + PEGPH20 pancreatic ca

T + BL-8040 pancreatic ca

INCY** Tecentriq + epacadostat solid tumors

CLDX** Tecentriq + varlilumab solid tumors

CRVS** Tecentriq + CPI-444 solid tumors

KITE** Tecentriq + KTE-C19 r/r DLBCL

AMGN** Tecentriq + talimogene laherp TNBC, CRC

JNJ** Tecentriq ± daratumumab solid tumors

CLVS** Tecentriq + rucaparib ovarian ca

EPZM** Tecentriq + tazemetostat r/r DLBCL

BLRX** Tecentriq + BL-8040 AML, solid tumors

Phase I (9 NMEs + 29 AIs) Phase III (17 AIs)

Registration (1 NME + 1 AIs) Phase II (4 AIs)

MORPHEUS Platform - Phase Ib/II (1 AI)


Doing now what patients need next

roche · •approved in ppms & rms (us) •positive early feedback from all stakeholders hy...

Documents